Prevention and management of ovarian hyperstimulation syndrome
- PMID: 28262238
- DOI: 10.1016/S0049-3848(17)30070-1
Prevention and management of ovarian hyperstimulation syndrome
Abstract
Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of ovarian stimulation. It is feasible to identify patients at risk, modify stimulation strategies to ameliorate risk, and initiate out-patient treatments that alter disease pathophysiology to reduce disease severity. Mitigation of OHSS risk and severity, through innovative approaches prior to treatment, during treatment and after treatment should now be standard care. This review summarizes recent developments and provides recommendations on the prevention and treatment of OHSS.
Keywords: IVF; Ovarian hyperstimulation syndrome (OHSS); Prevention; Treatment.
© 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence.Curr Drug Targets. 2013 Jul;14(8):843-9. doi: 10.2174/13894501113149990163. Curr Drug Targets. 2013. PMID: 23614678 Review.
-
Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.Semin Reprod Med. 2010 Nov;28(6):493-9. doi: 10.1055/s-0030-1265676. Epub 2010 Nov 16. Semin Reprod Med. 2010. PMID: 21082508 Review.
-
Prevention and management of ovarian hyperstimulation syndrome.Best Pract Res Clin Obstet Gynaecol. 2012 Dec;26(6):817-27. doi: 10.1016/j.bpobgyn.2012.04.004. Epub 2012 May 29. Best Pract Res Clin Obstet Gynaecol. 2012. PMID: 22647872
-
Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.Fertil Steril. 2015 Apr;103(4):870-3. doi: 10.1016/j.fertnstert.2015.02.004. Epub 2015 Feb 24. Fertil Steril. 2015. PMID: 25724740 Review.
-
Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.Reprod Biomed Online. 2009 Jul;19(1):43-51. doi: 10.1016/s1472-6483(10)60044-2. Reprod Biomed Online. 2009. PMID: 19573289
Cited by
-
Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view.Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):148-151. doi: 10.1182/hematology.2019000071. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808870 Free PMC article.
-
Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome.Int J Gynaecol Obstet. 2022 Dec;159(3):944-950. doi: 10.1002/ijgo.14264. Epub 2022 Jun 5. Int J Gynaecol Obstet. 2022. PMID: 35575072 Free PMC article.
-
Curcumin alleviates ovarian hyperstimulation syndrome in the rat model via inhibiting the nuclear factor kappa B/hypoxia-inducible factor-1α signaling pathway.Histochem Cell Biol. 2025 Jul 12;163(1):75. doi: 10.1007/s00418-025-02403-3. Histochem Cell Biol. 2025. PMID: 40650702
-
Severe Early-onset Ovarian Hyperstimulation Syndrome with Isolated Pleural Effusion following Agonist Trigger in Gonadotropin-releasing Hormone Antagonist Cycle: A Case Report.J Hum Reprod Sci. 2025 Apr-Jun;18(2):125-128. doi: 10.4103/jhrs.jhrs_39_25. Epub 2025 Jun 28. J Hum Reprod Sci. 2025. PMID: 40740628 Free PMC article.
-
An update of polycystic ovary syndrome: causes and therapeutics options.Heliyon. 2022 Oct 10;8(10):e11010. doi: 10.1016/j.heliyon.2022.e11010. eCollection 2022 Oct. Heliyon. 2022. PMID: 36267367 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources